2022
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2017
The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension.
Kim C, Salazar M, Hoag J, Rosen J, Arnold B, Boffa D, Blasberg J. The impact of tumor size on survival in T3 non-small cell lung-cancer with direct extension. Journal Of Clinical Oncology 2017, 35: e20033-e20033. DOI: 10.1200/jco.2017.35.15_suppl.e20033.Peer-Reviewed Original ResearchTumor sizeAdjuvant chemoradiationAdjuvant chemotherapyAdjuvant therapyOverall cohortInferior survivalCurrent staging guidelinesNational Cancer DatabaseImportant prognostic variablesSubset of patientsPathologic N stageLarger tumor sizeNon-small cellProportional hazards modelN0 patientsN2 patientsNeoadjuvant therapyNodal diseaseImproved survivalPositive marginsStaging guidelinesCancer DatabaseN stagePrognostic variablesHazards model